Home / Health / Western Pharma's China Gamble: Early Drug Tests Speed Up
Western Pharma's China Gamble: Early Drug Tests Speed Up
23 Oct
Summary
- Pharma groups use Chinese hospitals for early-stage drug testing.
- Investigator-initiated trials offer a faster route to human testing.
- China's trial enrollment is significantly faster than in the US.
Western pharmaceutical companies are leveraging Chinese hospitals to conduct early-stage clinical trials for experimental cell and gene therapies, marking a significant evolution in global drug development. Companies such as AstraZeneca, Sana Biotechnology, and Tempest Therapeutics are participating in investigator-initiated trials (IITs), a fast-track route that allows for human testing earlier than typically permitted elsewhere. This approach aims to generate preliminary data efficiently, potentially accelerating the path to market for novel treatments.
China's prominence in medical research is underscored by a surge in IITs, with 282 launched in 2025, a substantial increase from a decade prior. The country's extensive network of academic hospitals, specialized researchers, and a large patient population contribute to faster enrollment rates, reportedly two to five times quicker than in the US. This efficiency is crucial for first-in-human studies assessing safety and dosage.
Despite recent concerns over patient safety and two reported child deaths in gene-editing studies, alongside tightened regulations in China this year, the appeal of IITs persists. While new rules may cause some delays, industry experts believe they will not deter the overall trend. These trials de-risk drug candidates, potentially aiding in fundraising and acquisition opportunities for biotech firms.
